Driving Ability of Drug Dependant Patients in Maintenance Therapy

NCT ID: NCT01150435

Last Updated: 2010-06-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

121 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-29

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

"Mobility" is a contributing factor in today's society. Drug dependence displays not only a medical but also an economic problem: Especially for an intended reintegration of a drug dependant patient in maintenance therapy the possession of a driving licence could be decisive for a job allocation and therefore the intended reintegration to society.

Subject of this study was to verify if patients under substitution therapy with R, S- Methadone, S- Methadone, Buprenorphine and Buprenorphine plus Naloxone are just as fit to drive a car as a non drug dependent person.

For this investigation we compared 121 drug dependent patients in stable maintenance therapy for a minimum of two years without consumption of any other psychotropic substances than their maintenance drug (including THC) with non- drug dependant subjects of the same gender, age and level of education.

This is the largest study on this topic worldwide. The neuro- cognitive working order was tested by means of the "Vienna Test System" an objective, reliable and valid test quantifying reaction time, attention efficiency, concentration, maximum resilience and orientation. Current use of any other psychotropic substance or alcohol just as any serious illness (including psychiatric diseases, except for an effectively treated depression) lead to exclusion from this study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Driving Ability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Maintenance Medication D, S- Methadon

No interventions assigned to this group

Maintenance Medication S- Methadon

No interventions assigned to this group

Buprenorphine

No interventions assigned to this group

Buprenorphine+ Naloxone

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Drug dependent patients in stable maintenance therapy for a minimum of two years without consumption of any other psychotropic substances than their maintenance drug (including THC)
* Written agreement on attending this study after full clarification
* majority

Exclusion Criteria

* Patients, who do not approve or are not able to approve, to this study
* Patients, who are not legally competent
* Patients in emergency situations
* Patients under age
* Consumption of any other psychotropic substances than the maintenance drug
* Severe illnesses p.e. malignant diseases, serious psychiatric illness
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role collaborator

Hummel, Christiane

INDIV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christiane Hummel

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Gilg, Proffessor

Role: STUDY_DIRECTOR

Institut für Rechtsmedizin München

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut für Rechtsmedizin

Munich, Baveria, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Hummel 2010-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dose-response of Cannabis and Driving
NCT03656029 COMPLETED PHASE2
Influence of Medication on Functional Connectivity
NCT03612713 COMPLETED EARLY_PHASE1
Double-Blind Naltrexone in Kleptomania
NCT00332579 COMPLETED PHASE2